Souhaitez-vous accéder aux communiqués récents ?

Phase I/II studies will evaluate Zykadia(TM), INC280 and EGF816 in combination with Bristol-Myers Squibb's investigational immunotherapy Opdivo® Combination studies will evaluate compounds that...

Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen[1]  On all-cause mortality, LCZ696 doubled the effect...

LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF PARADIGM-HF is the largest heart failure...

Net sales grew 2%[1] in Q2, with core operating leverage across Q2 and H1 Net sales of USD 14.6 billion grew 2% (+2% cc[2]) in Q2; USD 28.7 billion (+2%, +2% cc) in H1 Strong operating income...

New Novartis focused on three leading businesses with innovation power and global scale Pharmaceuticals building business depth in Dermatology, Heart Failure, Respiratory and Cell Therapy,...

Litigation settlement upholds validity of US patents covering polymorphic forms of Gleevec and permits Sun Pharma subsidiary to launch a generic version on February 1, 2016  Patents are vital to...

Zykadia (ceritinib) demonstrated an overall response rate of 54.6% in patients with ALK+ metastatic NSCLC who have no other treatment option[1] Median duration of response to Zykadia was 7.4...

Net sales of USD 14.0 billion up 1%[1] (+3% cc[2]) with all divisions contributing to growth (cc); core operating leverage (cc) driven by Pharmaceuticals and lower Corporate costs Operating...

Acquires GSK oncology products, strengthening Novartis' leading Oncology business with novel therapies and becomes GSK's preferred commercialization partner for its oncology pipeline Combines...

New leaders to continue to build global scale and innovation power in two of the leading Novartis businesses Basel, April 9, 2014 - Novartis announced today the appointment of Jeff George as...